23.90
-1.12 (-4.48%)
| Previous Close | 25.02 |
| Open | 24.53 |
| Volume | 2,180,802 |
| Avg. Volume (3M) | 1,194,466 |
| Market Cap | 1,969,347,584 |
| Price / Book | 3.15 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Diluted EPS (TTM) | -3.75 |
| Current Ratio (MRQ) | 26.48 |
| Operating Cash Flow (TTM) | -192.66 M |
| Levered Free Cash Flow (TTM) | -122.17 M |
| Return on Assets (TTM) | -35.87% |
| Return on Equity (TTM) | -56.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Mineralys Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 103.83% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalys Pacific, Llc | 31 Dec 2025 | 7,903,838 |
| Samsara Biocapital, Llc | 31 Dec 2025 | 5,871,018 |
| Caligan Partners Lp | 31 Dec 2025 | 2,772,654 |
| Holocene Advisors, Lp | 31 Dec 2025 | 1,602,035 |
| Andera Partners | 31 Dec 2025 | 1,591,917 |
| Sr One Capital Management, Lp | 31 Dec 2025 | 1,563,966 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RODMAN DAVID MALCOM | - | 27.24 | -2,171 | -59,138 |
| Aggregate Net Quantity | -2,171 | |||
| Aggregate Net Value ($) | -59,138 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RODMAN DAVID MALCOM | Officer | 09 Mar 2026 | Automatic sell (-) | 2,171 | 27.24 | 59,138 |
| RODMAN DAVID MALCOM | Officer | 09 Mar 2026 | Option execute | 2,171 | - | - |
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |